Abstract
Various aspects of trial design and planning for clinical testing of antiemetic therapies administered to cancer patients are considered. It is generally felt that a randomized double-blind parallel-arm design is the best. Ways of achieving adequate power of such studies are discussed briefly, as is the need for previous identification of primary and secondary end-points. Finally, summary recommendations are given.
Publication types
-
Consensus Development Conference
-
Review
MeSH terms
-
Antiemetics / adverse effects
-
Antiemetics / therapeutic use*
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Data Interpretation, Statistical
-
Double-Blind Method
-
Humans
-
Neoplasms / drug therapy*
-
Randomized Controlled Trials as Topic / statistics & numerical data*
-
Treatment Outcome
-
Vomiting / chemically induced
-
Vomiting / drug therapy*
Substances
-
Antiemetics
-
Antineoplastic Agents